The researchers are doing this study to see if one session of high-dose contrast-enhanced MRI-guided SBRT (stereotactic body radiation therapy) is effective for colorectal cancer that has spread to the liver. The researchers will evaluate how well the study treatment can prevent the liver metastasis from growing and spreading. In addition, they will see whether it causes any side effects and whether there are any characteristics of the research MRI images that can predict response to treatment.
Age ≥18
Histologically confirmed colorectal carcinoma and evidence of liver metastasis on imaging
ECOG 0-2
<=3 liver lesions measurable on contrast enhanced diagnostic MRI with combined size (sum of longest diameters) < 7 cm, and individual size < 5cm. (Subsequent simulation scans will not be used for eligibility assessment. In case of significant change in size exceeding 1cm, the individual participants can continue on the protocol provided all normal tissue contraints are met during planning).
Any history of cirrhosis
History of hepatic radioembolization or selective internal radiation therapy (SIRT)
History of inflammatory bowel disease that precludes liver RT (at the discretion of the treating radiation oncologist).
Current pregnancy or breastfeeding
Single group
MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
Radiation40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
Local control rate CRC liver metastasis
by RECIST
Click on the lead sponsor to view all of their trials.
Memorial Sloan Kettering Cancer Center
Lead sponsor
Elekta Limited
Collaborator
